View in EDS

Real-World Treatment Patterns and Overall Survival (OS) of Patients with Metastatic Castration-Resistant Prostate Cancer in Italy.

Saved in:
Bibliographic Details
Title: Real-World Treatment Patterns and Overall Survival (OS) of Patients with Metastatic Castration-Resistant Prostate Cancer in Italy.
Authors: Dovizio, Melania, Castelletti, Daniela, Luraghi, Paolo, Losi, Serena, Gervasi, Andrea, Risi, Matteo, Leogrande, Melania, Esposti, Luca Degli, Procopio, Giuseppe
Source: Pragmatic & Observational Research; Nov2025, Vol. 16, p189-199, 11p
Subject Terms: CASTRATION-resistant prostate cancer, OVERALL survival, THERAPEUTICS, ANDROGEN receptors, CANCER chemotherapy, MEDICAL databases, ITALIAN history, SCIENTIFIC observation
Geographic Terms: ITALY
Abstract: Purpose: This real-world analysis described the characteristics and therapeutic management of patients with metastatic castration-resistant prostate cancer (mCRPC) in Italy before and after 2015, when androgen receptor signalling inhibitors (ARPI) entered clinical practice. Patients and Methods: An observational retrospective analysis was conducted using administrative healthcare databases from a pool of Italian Local Health Units, covering ~6.2 million residents. Adult men with ≥ 1 prescription of androgen deprivation therapy (ADT) from January 2011 to June 2022 were identified. mCRPC was proxied by treatment patterns—addition of docetaxel/cabazitaxel or ARPI to ADT—and confirmed by hospital discharge for metastasis. Patients were stratified according to their inclusion (date of the last inclusion criterion met): pre-2015 (2011– 2014) and post-2015 (2015– 2020). Results: Among 1890 mCRPC patients identified, 551 (29%) received ≥ 2 treatment lines. Chemotherapy (CHT) was the predominant first-line (1L) therapy in both cohorts [97.2% vs 82.9%], followed by ARPI [2.8% vs 17.1%]. In a 2020 sensitivity analysis (n=406), 1L therapy was ARPI in 76% and CHT in 24%. Among pre- and post-2015 patients, 29.4% and 31.6% received second-line (2L) therapy, mostly ARPI. Median OS from ADT initiation was 46.4 months (pre-2015) and 53.9 months (post-2015). In post-2015 patients, median OS from mCRPC index-date—reflecting the proxy-based diagnosis—was 14.2 months. Conclusion: In Italian clinical practice, CHT remains the most common 1L therapy though ARPI use has increased since 2015. While OS from ADT initiation has improved, survival from mCRPC diagnosis—based on proxies in administrative data—remains poor, underscoring an unmet clinical need. Differences in OS estimates depending on the starting point (ADT initiation vs mCRPC diagnosis) should be considered when interpreting results. [ABSTRACT FROM AUTHOR]
Copyright of Pragmatic & Observational Research is the property of Dove Medical Press Ltd and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Biomedical Index
Description
Abstract:Purpose: This real-world analysis described the characteristics and therapeutic management of patients with metastatic castration-resistant prostate cancer (mCRPC) in Italy before and after 2015, when androgen receptor signalling inhibitors (ARPI) entered clinical practice. Patients and Methods: An observational retrospective analysis was conducted using administrative healthcare databases from a pool of Italian Local Health Units, covering ~6.2 million residents. Adult men with ≥ 1 prescription of androgen deprivation therapy (ADT) from January 2011 to June 2022 were identified. mCRPC was proxied by treatment patterns—addition of docetaxel/cabazitaxel or ARPI to ADT—and confirmed by hospital discharge for metastasis. Patients were stratified according to their inclusion (date of the last inclusion criterion met): pre-2015 (2011– 2014) and post-2015 (2015– 2020). Results: Among 1890 mCRPC patients identified, 551 (29%) received ≥ 2 treatment lines. Chemotherapy (CHT) was the predominant first-line (1L) therapy in both cohorts [97.2% vs 82.9%], followed by ARPI [2.8% vs 17.1%]. In a 2020 sensitivity analysis (n=406), 1L therapy was ARPI in 76% and CHT in 24%. Among pre- and post-2015 patients, 29.4% and 31.6% received second-line (2L) therapy, mostly ARPI. Median OS from ADT initiation was 46.4 months (pre-2015) and 53.9 months (post-2015). In post-2015 patients, median OS from mCRPC index-date—reflecting the proxy-based diagnosis—was 14.2 months. Conclusion: In Italian clinical practice, CHT remains the most common 1L therapy though ARPI use has increased since 2015. While OS from ADT initiation has improved, survival from mCRPC diagnosis—based on proxies in administrative data—remains poor, underscoring an unmet clinical need. Differences in OS estimates depending on the starting point (ADT initiation vs mCRPC diagnosis) should be considered when interpreting results. [ABSTRACT FROM AUTHOR]
ISSN:11797266
DOI:10.2147/POR.S539229